Duality Biologics and BioNTech shared encouraging interim findings for their experimental B7-H3 antibody-drug conjugate BNT324/DB-1311.

Simcha Therapeutics has announced the initiation of two clinical trials evaluating ST-067, their decoy-resistant IL-18, for hematological conditions.

Merck and Ridgeback Biotherapeutics have started a Phase 3 trial (MOVe-NOW) to assess LAGEVRIO™ (molnupiravir) in treating COVID-19 among high-risk adults.

IMFINZI® (durvalumab) has been authorized in the US as the first and sole immunotherapy treatment for patients with limited-stage small cell lung cancer.

Elritercept is an advanced investigational activin inhibitor aimed at treating anemia linked with specific hematologic malignancies.

Arrowhead Pharmaceuticals Seeks Approval to Start Phase 1/2a Trial of ARO-ALK7 for Obesity Treatment.

Jasper Therapeutics has reported the initial patient receiving treatment in the Phase 1b/2a ETESIAN trial of Briquilimab for asthma.

Epsilogen has declared the initiation of a Phase Ib trial assessing MOv18 IgE in individuals suffering from platinum-resistant ovarian cancer (PROC).

OncoC4 has received FDA approval for its IND application regarding AI-081, a promising PD-1/VEGF bispecific therapy for advanced solid tumors.

TORL BioTherapeutics has named Aran Maree, M.D., as its Chief Medical Officer and has begun a Phase 2 study for TORL-1-23.

Spyre Therapeutics Reports First Dosing of Participants in Phase 1 Trials for New Extended Half-Life Anti-TL1A Antibodies.

The U.S. FDA has given the green light to Biocon Biologics' biosimilar YESINTEK™, Bmab 1200, which is comparable to J&J's Stelara® (Ustekinumab).